Peter J. Reddig

Array ( [id] => 15099523 [patent_doc_number] => 10471055 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Methods of treating cancer patients with farnesyltransferase inhibitors [patent_app_type] => utility [patent_app_number] => 15/238458 [patent_app_country] => US [patent_app_date] => 2016-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 67695 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15238458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311463 [patent_doc_number] => 20180207268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => COMBINATION THERAPY FOR CANCER [patent_app_type] => utility [patent_app_number] => 15/745451 [patent_app_country] => US [patent_app_date] => 2016-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6794 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15745451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413158 [patent_doc_number] => 11667691 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Treatment of cancer using chimeric CD3 receptor proteins [patent_app_type] => utility [patent_app_number] => 15/750796 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 40835 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16216368 [patent_doc_number] => 10732170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => Quality of immunological synapse predicts effectiveness of chimeric antigen receptor (CAR) T cells [patent_app_type] => utility [patent_app_number] => 15/749445 [patent_app_country] => US [patent_app_date] => 2016-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 25 [patent_no_of_words] => 12381 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 249 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15749445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13369025 [patent_doc_number] => 20180236053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING CD38 ANTIGEN AND FOR CD38 GENE INACTIVATION [patent_app_type] => utility [patent_app_number] => 15/751472 [patent_app_country] => US [patent_app_date] => 2016-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16429664 [patent_doc_number] => 10829735 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-10 [patent_title] => Methods for improving the efficacy and expansion of immune cells [patent_app_type] => utility [patent_app_number] => 15/216036 [patent_app_country] => US [patent_app_date] => 2016-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 92 [patent_no_of_words] => 99619 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15216036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15663911 [patent_doc_number] => 10596162 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Method for treating gefitinib resistant cancer [patent_app_type] => utility [patent_app_number] => 15/207349 [patent_app_country] => US [patent_app_date] => 2016-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 10624 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15207349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12880777 [patent_doc_number] => 20180185434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => IMMUNE CHECKPOINT CHIMERIC ANTIGEN RECEPTORS THERAPY [patent_app_type] => utility [patent_app_number] => 15/740981 [patent_app_country] => US [patent_app_date] => 2016-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15740981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12880519 [patent_doc_number] => 20180185348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => IMMUNOTHERAPEUTIC DOSING REGIMENS COMPRISING POMALIDOMIDE AND AN ANTI-CS1 ANTIBODY FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/738412 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15738412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414543 [patent_doc_number] => 10822419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Masking chimeric antigen receptor T cells for tumor-specific activation [patent_app_type] => utility [patent_app_number] => 15/574743 [patent_app_country] => US [patent_app_date] => 2016-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 19632 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15574743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13887763 [patent_doc_number] => 10196422 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers [patent_app_type] => utility [patent_app_number] => 15/191895 [patent_app_country] => US [patent_app_date] => 2016-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 7 [patent_no_of_words] => 34830 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15191895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350250 [patent_doc_number] => 20160368990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'ANTI B7-H3 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/187209 [patent_app_country] => US [patent_app_date] => 2016-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 39765 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15187209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12880660 [patent_doc_number] => 20180185395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => ANTICANCER AGENT [patent_app_type] => utility [patent_app_number] => 15/736561 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862324 [patent_doc_number] => 20180179282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => TREATMENT OF CANCER BY COMBINED BLOCKADE OF THE PD-1 AND CXCR4 SIGNALING PATHWAYS [patent_app_type] => utility [patent_app_number] => 15/735055 [patent_app_country] => US [patent_app_date] => 2016-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15735055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311745 [patent_doc_number] => 20160347855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/181019 [patent_app_country] => US [patent_app_date] => 2016-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 69 [patent_no_of_words] => 46538 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15181019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11335605 [patent_doc_number] => 20160361360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'DISEASE THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND T CELLS (CAR-T) OR NK CELLS (CAR-NK) EXPRESSING CAR CONSTRUCTS' [patent_app_type] => utility [patent_app_number] => 15/179472 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 34649 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15179472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13037487 [patent_doc_number] => 10040863 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-07 [patent_title] => Anticancer agent [patent_app_type] => utility [patent_app_number] => 15/166647 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 24 [patent_no_of_words] => 11072 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15166647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11310217 [patent_doc_number] => 20160346326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'Methods of Conditioning Patients for T Cell Therapy' [patent_app_type] => utility [patent_app_number] => 15/167977 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 38563 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15167977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11555439 [patent_doc_number] => 20170101685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'DIAGNOSTIC METHOD' [patent_app_type] => utility [patent_app_number] => 15/162258 [patent_app_country] => US [patent_app_date] => 2016-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8829 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15162258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060784 [patent_doc_number] => 20160257746 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/160742 [patent_app_country] => US [patent_app_date] => 2016-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 41024 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15160742 [rel_patent_id] =>[rel_patent_doc_number] =>)